The New England journal of medicine
-
Letter Case Reports
Combined aortic surgery and implantation of a left ventricular assist device.
-
Multicenter Study Clinical Trial
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. ⋯ Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.